Clinical Biomarkers – A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, Application, End User, and Region – Analysis and Forecast, 2022-2032

$5250$8100

In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032.

SKU: BHP0826SB Category: Tag:

Description

Global Clinical Biomarkers Market Industry Overview

In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032. The growth in the global clinical biomarkers market is expected to be driven by the increasing demand for clinical biomarker products, increasing key player initiatives, and increasing prevalence of infectious diseases and various types of cancer globally.

Market Lifecycle Stage

Breast Cancer Awareness Month Clinical BiomarkersClinical biomarkers have been extensively preferred in the field of clinical medicine to offer individualized treatment options to patients. Biomarkers are crucial to the rational development of medical therapeutics and are involved in their use in in-vitro diagnostics purposes, particularly in the fields of chronic disease and nutrition.

Companies such as Illumina, Inc., F. Hoffmann-La Roche Ltd Agilent Technologies, Inc., and Myriad Genetics, Inc., in the clinical biomarkers market are launching products, majorly focusing on indications for infectious diseases and cancer types such as breast cancer, ovarian cancer, lung cancer, and cervical cancer. Several companies, such as Thermo Fisher Scientific Inc., QIAGEN N.V., NeoGenomics Laboratories, and CENTOGENE N.V., are collaborating and partnering with the stakeholders to develop and expand technological expertise to offer potential products in the global clinical biomarkers market. Breast cancer is the most frequent tumor growth in women, and its incidence experienced innovation in systematic screening. The increasing incidence of breast cancer has led to an increase in demand for its diagnosis and treatment.

Impact

• Increasing demand for clinical biomarkers products is anticipated to support the growth of the global clinical biomarkers market during the forecast period 2022-2032.
• The market is expected to grow at a significant growth rate due to opportunities such as the expansion of biomarker discovery and increased research funding for executing research and development exercises.

Impact of COVID-19

The current global clinical biomarkers market comprises various applications such as translational research and clinical diagnostic. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, which has led to reduced usage of various products and services related to research.

The government imposed various restrictions during COVID-19, such as travel bans, quarantines, curfews, business shutdowns, and closures. This led to an increased cost of COVID-19-related services. There have been many issues during the COVID-19 pandemic, such as operational failures, shipping issues, inaccurate demand forecasts, and other production issues.

Furthermore, the health and safety of employees were impacted as COVID-19 reduced the efficacy of employees’ work potential. However, the market related to COVID-19 grew during the pandemic as customers were in need of testing services. The implementation of lockdown and travel restrictions amidst the pandemic shook the entire clinical biomarkers industry globally, leading to manufacturing difficulties and delays in clinical trials of biomarkers.

The following section represents how the COVID-19 crisis is dismantling drug manufacturing along with the other industry sectors that rely on drug discovery and development, disease risk assessment, and others. The pandemic has impacted the clinical biomarkers market, resulting in fewer sales of the services. Furthermore, the sales of products and services would grow after COVID-19, resulting in better-operating outcomes. However, things have been better after the removal of various restrictions and lockdowns imposed by governments.

Market Segmentation:

Segmentation 1: by Offering
• Product
• Service

Based on offering, with respect to the overall market share, the service segment held the largest share, i.e., 55.41% of the global clinical biomarkers market in 2021. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 52.88% share in 2032. The high share of the service segment is majorly due to the rising demand for clinical biomarkers services in oncology, the rising number of product launches and approval in recent years, and increasing emphasis on the adoption of clinical biomarkers technologies.

Segmentation 2: by Technology
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Other Technologies

Based on technology, in 2021, global clinical biomarkers market was dominated by next-generation sequencing, with a massive market share of 31.28%. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 34.34% share in 2032. This is primarily due to the growing cancer genomics research.

Segmentation 3: by Application
• Clinical Diagnostic
• Translational Research

Based on application, the translational research segment accounted for the largest share in 2021, holding a 53.03% market share. This trend is expected to continue during the forecast period 2022-2032, with the translational research segment expecting to have a 54.11% share of the market in 2032.

Segmentation 4: Clinical Area
Cancer Biomarker
• Cardiac Biomarker
• Neurological Biomarker
• Infectious Disease Biomarker
• Immunological Biomarker
• Non-Invasive Prenatal Testing
• Other Clinical Areas

Based on clinical area, the cancer biomarkers segment accounted for the largest share in 2021, holding a 42.04% market share. This trend is expected to continue during the forecast period 2022-2032. Increasing cancer cases across the globe will contribute significantly to the growth of this market.

Segmentation 5: by End User
• Contract Research Organizations (CROs)
• Research and Academic Laboratories
• Biopharmaceutical and Biotech Companies
• Diagnostic Centers
• Other End Users

Based on end user, the contract research organizations (CROs) segment accounted for the largest share in 2021, holding a 35.69% market share. This trend is expected to continue during the forecast period 2022-2032.

Segmentation 6: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

The North America region is expected to dominate the global clinical biomarkers market during the forecast period 2022-2032. North America has a high adoption rate of cancer genomics research. Backed by several healthcare companies working in the marketplace, the U.S. has the highest implementation of PCR, NGS, and other technologies.

Recent Developments in the Global Clinical Biomarkers Market

• Acquisition in 2021: NeoGenomics Laboratories acquired Inivata. With this acquisition, the company strengthened its market position and expanded its footprint in the clinical biomarkers market.
• Collaboration: In 2022, F. Hoffmann-La Roche Ltd collaborated with Nordic Bioscience to strengthen the development of biomarkers for chronic diseases.
• Product Approval: In 2020, F. Hoffmann-La Roche Ltd received FDA approval for an assay to detect the HER2 biomarker in breast cancer.

Demand – Drivers and Limitations

Following are the demand drivers for the clinical biomarkers market:

• Increasing Demand for Clinical Biomarker Products
• Increasing Key Player Initiatives
• Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally

The market is expected to face some limitations due to the following challenges:

• Higher Price of Product/Service Hampering the Expansion in Low-Income countries
• Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests
• Lack of Qualified Professionals

How can this report add value to an organization?

Product/Innovation Strategy: Product launches and upgrades in the clinical biomarkers industry are aimed at advancing the overall technologies in the market to ensure efficient detection of various applications such as forensic and paternity identification. Several companies, including Thermo Fisher Scientific Inc. and QIAGEN N.V., were involved in product innovations.

Competitive Strategy: Enterprises led by market juggernauts frequently update their product portfolios with innovative and application-specific products to sustain current market competition. Moreover, a detailed competitive benchmarking of the players operating in the global clinical biomarkers market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• Abbott.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• NeoGenomics Laboratories
• Charles River Laboratories
• F. Hoffmann-La Roche Ltd
• Quest Diagnostics Incorporated
• Enzo Biochem Inc.
• ALCEN
• Myriad Genetics, Inc.
• CENTOGENE N.V.
• bioMérieux S.A.
• Arsenal Capital Partners
• Novogene Co., Ltd.
• Q2 Solutions
• Caris Life Sciences
• Broad Institute
• Personalis Inc.
• Azenta Life Sciences
• Discovery Life Sciences(DLS)
• BGI
• Eurofins Scientific
• Becton, Dickinson and Company

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Base Year

2022

Base Market Size

$23, 507.6 Million in 2022

Currency

USD

Forecast Year

2032

Market Size Forecast

$54, 294.0 Million by 2032

CAGR

8.73%

Table of Contents

1 Market 1.1 Product Definition 1.2 Inclusion and Exclusion 2 Market Scope 2.1 Key Questions Answered in the Report 3 Research Methodology 3.1 Data Sources 3.1.1 Primary Data Source 3.1.2 Secondary Data Sources 3.1.2.1 Open Sources 3.2 Market Estimation Model 3.3 Criteria for Company Profiling 4 Market Overview 4.1 Introduction 4.2 Clinical Biomarkers Approaches in Precision Medicine 4.3 Market Size Potential for Clinical Biomarkers, 2021-2032 4.4 COVID-19 Impact on Global Clinical Biomarkers Market 4.4.1 Impact on Market Size 5 Market Dynamics 5.1 Impact Analysis 5.2 Market Drivers 5.2.1 Increasing Demand for Clinical Biomarker Products 5.2.2 Rising Key Player Initiatives 5.2.3 Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally 5.3 Market Challenges 5.3.1 Higher Price of Product/Service Hampering the Expansion in Low-Income countries 5.3.2 Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests 5.3.3 Lack of Qualified Professionals 5.4 Market Opportunities 5.4.1 Technological Advancement in Biomarker Discovery 5.4.2 Increased Research Funding for Executing Research and Development Exercise 6 Industry Insights 6.1 Regulatory Framework 6.1.1 Regulatory Framework in the U.S 6.1.2 FDA Regulations 6.1.3 Biomarker Qualification: Evidentiary Framework Guidance for Industry and FDA Staff 6.1.4 Regulatory Framework in the U.S. for Medical Devices 6.1.5 Legal Requirements and Framework in Europe 6.1.5.1 U.K. 6.1.5.2 Germany 6.1.6 Legal Requirements and Framework in Asia-Pacific 6.1.6.1 China 6.1.6.2 Japan 6.1.6.2.1 Pharmaceuticals and Medical Devices Agency (PMDA) 6.2 Patent Analysis 7 Competitive Insights 7.1 Corporate Strategies 7.1.1 Acquisitions 7.1.2 Synergistic Activities 7.1.3 Funding and Business Expansions 7.2 Business Strategies 7.2.1 Service/Product Launches 7.3 Supply Chain Analysis 7.4 Pricing Analysis 7.4.1 Pricing Analysis by Product 7.4.2 Pricing Analysis by Testing Services 7.5 Market Share Analysis (by Product Manufacturer) 7.6 Market Share Analysis (by Service Provider) 7.7 Growth-Share Analysis (by Product Manufacturer) 7.8 Growth-Share Analysis (by Service Provider) 7.9 Growth-Share Analysis (Application) 7.1 Growth-Share Analysis (End User) 8 Global Clinical biomarkers market, by Offering, $Million, 2021-2032 8.1 Overview 8.2 Product 8.2.1 Efficacy Biomarker 8.2.1.1 Diagnostic Biomarker 8.2.1.2 Predictive Biomarker 8.2.1.3 Prognostic Biomarker 8.2.2 Safety Biomarker 8.2.3 Validation Biomarker 8.3 Service 8.3.1 Genomic Biomarker Service 8.3.2 Tissue Biomarker Service 8.3.3 Cell Service 8.3.4 Proteomics Service 9 Global Clinical biomarkers market, by Technology, $Million, 2021-2032 9.1 Overview 9.2 Next-Generation Sequencing (NGS) 9.3 Polymerase Chain Reaction (PCR) 9.4 Immunohistochemistry (IHC) 9.5 Enzyme-Linked Immunosorbent Assay (ELISA) 9.6 Other Technologies 10 Global Clinical Biomarkers Market, by Clinical Area, $Million, 2021-2032 10.1 Overview 10.2 Cancer Biomarker 10.2.1 Breast Cancer Biomarker 10.2.2 Lung Cancer Biomarker 10.2.3 Colorectal Cancer Biomarker 10.2.4 Prostate Cancer Biomarker 10.2.5 Other 10.3 Cardiac Biomarker 10.4 Neurological Biomarker 10.5 Infectious Disease Biomarker 10.6 Non-Invasive Prenatal Testing 10.7 Immunological Biomarker 10.8 Other Clinical Areas 11 Global Clinical biomarkers Market, by Application, $Million, 2021-2032 11.1 Overview 11.1.1 Translational Research 11.1.2 Clinical Diagnostic 12 Global Clinical Biomarkers Market, by End User, $Million, 2021-2032 12.1 Overview 12.1.1 Contract Research Organizations (CROs) 12.1.2 Research and Academic Laboratories 12.1.3 Diagnostic Centers 12.1.4 Biopharmaceutical and Biotech Companies 12.1.5 Other End Users 13 Region 13.1 Overview 13.2 North America 13.2.1 U.S. 13.2.2 Canada 13.3 Europe 13.3.1 Germany 13.3.2 France 13.3.3 U.K. 13.3.4 Italy 13.3.5 Spain 13.3.6 Rest-of-Europe 13.4 Asia-Pacific 13.4.1 China 13.4.2 India 13.4.3 Japan 13.4.4 South Korea 13.4.5 Australia 13.4.6 Rest-of-Asia-Pacific 13.5 Latin America 13.5.1 Brazil 13.5.2 Mexico 13.5.3 Rest-of-Latin America 13.6 Rest-of-the-World 14 Market - Company Profiles 14.1 Overview 14.2 Abbott. 14.2.1 Company Overview 14.2.2 Role of Abbott. in the Global Clinical Biomarkers Market 14.2.3 Key Competitors of the Company 14.2.4 Corporate Strategies 14.2.5 Business Strategies 14.2.6 Financials 14.2.7 Key Insights about the Financial Health of the Company 14.2.8 Analyst’s Perspective 14.3 Agilent Technologies, Inc. 14.3.1 Company Overview 14.3.2 Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market 14.3.3 Key Competitors of the Company 14.3.4 Corporate Strategies 14.3.5 Financials 14.3.6 Key Insights about the Financial Health of the Company 14.3.7 Analyst’s Perspective 14.4 Bio-Rad Laboratories, Inc. 14.4.1 Company Overview 14.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market 14.4.3 Key Competitors of the Company 14.4.4 Financials 14.4.5 Key Insights about the Financial Health of the Company 14.4.6 Analyst’s Perspective 14.5 Illumina, Inc. 14.5.1 Company Overview 14.5.2 Role of Illumina, Inc. in the Global Clinical Biomarkers Market 14.5.3 Key Competitors of the Company 14.5.1 Corporate Strategies 14.5.2 Financials 14.5.3 Key Insights about the Financial Health of the Company 14.5.4 Analyst’s Perspective 14.6 PerkinElmer Inc. 14.6.1 Company Overview 14.6.2 Role of PerkinElmer Inc. in the Global Clinical Biomarkers Market 14.6.3 Key Competitors of the Company 14.6.4 Financials 14.6.5 Key Insights about the Financial Health of the Company 14.6.6 Analyst’s Perspective 14.7 QIAGEN N.V. 14.7.1 Company Overview 14.7.2 Role of QIAGEN N.V. in the Global Clinical Biomarkers Market 14.7.3 Key Competitors of the Company 14.7.4 Key Customers of the Company 14.7.5 Corporate Strategies 14.7.6 Business Strategies 14.7.7 Financials 14.7.8 Key Insights about the Financial Health of the Company 14.7.9 Analyst’s Perspective 14.8 Thermo Fisher Scientific Inc. 14.8.1 Company Overview 14.8.2 Role of Thermo Fisher Scientific Inc. in the Global Clinical Biomarkers Market 14.8.3 Key Competitors of the Company 14.8.4 Business Strategies 14.8.5 Corporate Strategies 14.8.6 Financials 14.8.7 Key Insights about the Financial Health of the Company 14.8.8 Analyst’s Perspective 14.9 NeoGenomics Laboratories 14.9.1 Company Overview 14.9.2 Role of NeoGenomics Laboratories in the Global Clinical Biomarkers Market 14.9.3 Key Competitors of the Company 14.9.4 Key Customers of the Company 14.9.5 Business Strategies 14.9.6 Financials 14.9.7 Key Insights about the Financial Health of the Company 14.9.8 Analyst’s Perspective 14.1 Charles River Laboratories 14.10.1 Company Overview 14.10.2 Role of Charles River Laboratories in the Global Clinical Biomarkers Market 14.10.3 Financials 14.10.4 Analyst’s Perspective 14.11 F. Hoffmann-La Roche Ltd 14.11.1 Company Overview 14.11.2 Role of F. Hoffmann-La Roche Ltd in the Global Clinical Biomarkers Market 14.11.3 Key Competitors of the Company 14.11.4 Business Strategies 14.11.5 Corporate Strategies 14.11.6 Financials 14.11.7 Key Insights about the Financial Health of the Company 14.11.8 Analyst’s Perspective 14.12 Quest Diagnostics Incorporated 14.12.1 Company Overview 14.12.2 Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers Market 14.12.3 Key Competitors of the Company 14.12.4 Financials 14.12.5 Analyst Perspective 14.13 Enzo Biochem Inc. 14.13.1 Company Overview 14.13.2 Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market 14.13.3 Key Competitors of the Company 14.13.4 Financials 14.13.5 Key Insights about the Financial Health of the Company 14.13.6 Analyst’s Perspective 14.14 ALCEN 14.14.1 Company Overview 14.14.2 Role of ALCEN in Global Clinical Biomarkers Market 14.14.3 Analyst’s Perspective 14.15 Myriad Genetics, Inc. 14.15.1 Company Overview 14.15.2 Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market 14.15.3 Corporate Strategies 14.15.4 Financials 14.15.5 Key Insights about the Financial Health of the Company 14.15.6 Analyst’s Perspective 14.16 CENTOGENE N.V. 14.16.1 Company Overview 14.16.2 Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market 14.16.3 Business Strategies 14.16.4 Financials 14.16.5 Key Insights about the Financial Health of the Company 14.16.6 Analyst’s Perspective 14.17 bioMérieux S.A. 14.17.1 Company Overview 14.17.2 Role of bioMérieux S.A. in the Global Clinical Biomarkers Market 14.17.3 Corporate Strategies 14.17.4 Business Strategies 14.17.5 Financials 14.17.6 Analyst’s Perspective 14.18 Arsenal Capital Partners 14.18.1 Company Overview 14.18.2 Role of Arsenal Capital Partners in the Global Clinical Biomarkers Market 14.18.3 Business Strategies 14.18.4 Analyst’s Perspective 14.19 Novogene Co., Ltd. 14.19.1 Company Overview 14.19.2 Role of Novogene Co., Ltd. in the Global Clinical Biomarkers Market 14.19.3 Analyst’s Perspective 14.2 Q2 Solutions 14.20.1 Company Overview 14.20.2 Role of Q2 Solutions in the Global Clinical Biomarkers Market 14.20.3 Business Strategies 14.20.4 Analyst’s Perspective 14.21 Caris Life Sciences 14.21.1 Company Overview 14.21.2 Role of Caris Life Sciences in the Global Clinical Biomarkers Market 14.21.3 Analyst’s Perspective 14.22 Broad Institute 14.22.1 Company Overview 14.22.2 Role of Broad Institute in the Global Clinical Biomarkers Market 14.22.3 Analyst’s Perspective 14.23 Personalis Inc. 14.23.1 Company Overview 14.23.2 Role of Personalis Inc. in the Global Clinical Biomarkers Market 14.23.3 Key Competitors of the Company 14.23.4 Key Customers of the Company 14.23.5 Business Strategies 14.23.6 Corporate Strategies 14.23.7 Financials 14.23.8 Key Insights about the Financial Health of the Company 14.23.9 Analyst’s Perspective 14.24 Azenta Life Sciences 14.24.1 Company Overview 14.24.2 Role of Azenta Life Sciences in the Global Clinical Biomarkers Market 14.24.3 Business Strategies 14.24.4 Analyst’s Perspectives 14.25 Discovery Life Sciences(DLS) 14.25.1 Company Overview 14.25.2 Role of Discovery Life Sciences in the Global Clinical Biomarkers Market 14.25.3 Key Partners 14.25.4 Business Strategies 14.25.5 Analyst’s Perspective 14.26 BGI 14.26.1 Company Overview 14.26.2 Role of BGI in Global Clinical Biomarkers Market 14.26.3 Corporate Strategies 14.26.4 Analyst’s Perspective 14.27 Eurofins Scientific 14.27.1 Company Overview 14.27.2 Role of Eurofins Scientific in the Global Clinical Biomarkers Market 14.27.3 Key Competitors of the Company 14.27.4 Corporate Strategies 14.27.5 Financials 14.27.6 Analyst’s Perspective 14.28 Becton, Dickinson and Company 14.28.1 Company Overview 14.28.2 Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market 14.28.3 Financials 14.28.4 Key Insights about the Financial Health of the Company 14.28.5 Analyst’s Perspective List of Figures Figure 1: Global Clinical Biomarkers Market Dynamics Figure 2: Global Clinical Biomarkers Market (by Offering), $Million, 2021 and 2032 Figure 3: Global Clinical Biomarkers Market (by Application), $Million, 2021 and 2032 Figure 4: Global Clinical Biomarkers Market (by Technology), $Million, 2021 and 2032 Figure 5: Global Clinical Biomarkers Market (by Clinical Area), $Million, 2021 and 2032 Figure 6: Global Clinical Biomarkers Market (by End User), $Million, 2021 and 2032 Figure 7: Global Clinical Biomarkers Market (by Region), $Million, 2021 Figure 8: Global Clinical Biomarkers Market Research Methodology Figure 9: Primary Research Methodology Figure 10: Bottom-Up Approach (Segment-Wise Analysis) Figure 11: Top-Down Approach (Segment-Wise Analysis) Figure 12: Biomarkers Used in Various Clinical Areas Figure 13: Leading Segments of the Global Clinical Biomarkers Market, 2021 and 2032 Figure 14: Global Clinical Biomarkers Market, $Million, 2021-2032 Figure 15: Pre-COVID-19 and Post-COVID-19 Scenario of Global Clinical Biomarkers Market, $Million, 2019-2025 Figure 16: Impact of COVID-19 on Clinical Biomarkers Market Figure 17: Global Clinical Biomarkers Market Dynamics Figure 18: Percentage of People Reporting Chronic Lower Respiratory Diseases in Europe Region, 2019 Figure 19: Cancer Cases in U.S., 2021 Figure 20: NIH Funding, 2019-2022 Figure 21: Responsibilities of the National Medical Products Administration (NMPA) Figure 22: Synergistic Activities Share (by Company), January 2019-July 2022 Figure 23: Funding and Business Expansions (by Company), January 2019-July 2022 Figure 24: Service/Product Launches (by Key Companies), January 2019-July 2022 Figure 25: Clinical Biomarkers Supply Chain Analysis Figure 26: Global Clinical Biomarkers Market Share Analysis (by Product Manufacturer), 2020 and 2021 Figure 27: Global Clinical Biomarkers Market Share Analysis (by Service Provider), 2020 and 2021 Figure 28: Growth-Share Analysis for Global Clinical Biomarkers Market (by Product Manufacturer) Figure 29: Growth-Share Analysis for Global Clinical Biomarkers Market (by Service Provider) Figure 30: Growth Share Analysis for Global Clinical Biomarkers Market (by Application), 2021-2032 Figure 31: Growth Share Analysis for Global Clinical Biomarkers Market (by End User), 2021-2032 Figure 32: Global Clinical Biomarkers Market (by Offering) Figure 33: Share of Global Clinical Biomarkers Market (by Offering), $Million, 2021 and 2032 Figure 34: Share of Global Clinical Biomarkers Market (by Product), $Million, 2021 and 2032 Figure 35: Global Clinical Biomarkers Market (Product), $Million, 2021-2032 Figure 36: Global Clinical Biomarkers Market (Efficacy Biomarker), $Million, 2021-2032 Figure 37: Global Clinical Biomarkers Market (Diagnostic Biomarker), $Million, 2021-2032 Figure 38: Role and Example of Predictive Biomarker Figure 39: Global Clinical Biomarkers Market (Predictive Biomarker), $Million, 2021-2032 Figure 40: Global Clinical Biomarkers Market (Prognostic Biomarker), $Million, 2021-2032 Figure 41: Global Clinical Biomarkers Market (Safety Biomarker), $Million, 2021-2032 Figure 42: Global Clinical Biomarkers Market (Validation Biomarker), $Million, 2021-2032 Figure 43: Share of Global Clinical Biomarkers Market (by Service), $Million, 2021 and 2032 Figure 44: Global Clinical Biomarkers Market (Service), $Million, 2021-2032 Figure 45: Global Clinical Biomarkers Market (Genomic Biomarker Service), $Million, 2021-2032 Figure 46: Global Clinical Biomarkers Market (Tissue Biomarker Service), $Million, 2021-2032 Figure 47: Global Clinical Biomarkers Market (Cell Service), $Million, 2021-2032 Figure 48: Global Clinical Biomarkers Market (Proteomics Service), $Million, 2021-2032 Figure 49: Global Clinical Biomarkers Market (by Technology) Figure 50: Global Clinical Biomarkers Market (by Technology), $Million, 2021 and 2032 Figure 51: Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology Figure 52: Global Clinical Biomarkers market (Next-Generation Sequencing), $Million, 2021-2032 Figure 53: Global Next-Generation Sequencing Market (Service), $Million, 2021-2032 Figure 54: Application of PCR Figure 55: Global Clinical Biomarkers Market (Polymerase Chain Reaction), $Million, 2021-2032 Figure 56: Global Polymerase Chain Reaction Market (Service), $Million, 2021-2032 Figure 57: Global Clinical Biomarkers Market (Immunohistochemistry (IHC)), $Million, 2021-2032 Figure 58: Global Immunohistochemistry (IHC) Market (Service), $Million, 2021-2032 Figure 59: Global Clinical Biomarkers Market Enzyme-Linked Immunosorbent Assay (ELISA)), $Million, 2021-2032 Figure 60: Global Enzyme-Linked Immunosorbent assay (ELISA) Market (Service), $Million, 2021-2032 Figure 61: Global Clinical Biomarkers Market (Other Technologies), $Million, 2021-2032 Figure 62: Global Other Technology Market (Service), $Million, 2021-2032 Figure 63: Global Clinical Biomarkers Market (by Clinical Area) Figure 64: Global Clinical Biomarkers Market (by Clinical Area), $Million, 2021 and 2032 Figure 65: Global Clinical Biomarkers Market (Cancer Biomarker), $Million, 2021-2032 Figure 66: Global Clinical Biomarkers Market (Breast Cancer Biomarker), $Million, 2021-2032 Figure 67: Global Clinical Biomarkers Market (Lung Cancer Biomarker), $Million, 2021-2032 Figure 68: Global Clinical Biomarkers Market (Colorectal Cancer Biomarker), $Million, 2021-2032 Figure 69: Global Clinical Biomarkers Market (Prostate Cancer Biomarker), $Million, 2021-2032 Figure 70: Global Clinical Biomarkers Market (Other), $Million, 2021-2032 Figure 71: Global Clinical Biomarkers Market (Cardiac Biomarker), $Million, 2021-2032 Figure 72: Global Clinical Biomarkers Market (Neurological Biomarker), $Million, 2021-2032 Figure 73: Global Clinical Biomarkers Market (Infectious Disease Biomarker), $Million, 2021-2032 Figure 74: Global Clinical Biomarkers Market Non-Invasive Prenatal Testing (NIPT)), $Million, 2021-2032 Figure 75: Global Clinical Biomarkers Market (Immunological Biomarker), $Million, 2021-2032 Figure 76: Global Clinical Biomarkers market (Other Clinical Areas), $Million, 2021-2032 Figure 77: Global Clinical Biomarkers Market (by Application) Figure 78: Global Clinical Biomarkers Market (by Application), 2021 vs. 2032 Figure 79: Global Clinical Biomarkers Market (Translational Research), $Million, 2021-2032 Figure 80: Global Clinical Biomarkers Market (Clinical Diagnostic), $Million, 2021-2032 Figure 81: Global Clinical Biomarkers Market (by End User), 2021 vs. 2032 Figure 82: Global Clinical Biomarkers Market (Contract Research Organizations (CROs)), $Million, 2021-2032 Figure 83: Global Clinical Biomarkers Market (Research and Academic Laboratories), $Million, 2021-2032 Figure 84: Global Clinical Biomarkers Market (Diagnostic Centers), $Million, 2021-2032 Figure 85: Global Clinical Biomarkers Market (Biopharmaceutical and Biotech Companies), $Million, 2021-2032 Figure 86: Global Clinical Biomarkers Market (Other End Users), $Million, 2021-2032 Figure 87: Global Clinical Biomarkers Market Snapshot (by Region), $Million, 2021-2032 Figure 88: Global Clinical Biomarkers Market (by Region), $Million, 2021-2032 Figure 89: Global Clinical Biomarkers Market (by Region), $Million, 2021 and 2032 Figure 90: North America Clinical Biomarkers Market, $Million, 2021-2032 Figure 91: North America: Market Dynamics Figure 92: North America Clinical Biomarkers Market (by Country), $Million, 2021-2032 Figure 93: U.S. Clinical Biomarkers Market, $Million, 2021-2032 Figure 94: Canada Clinical Biomarkers Market, $Million, 2021-2032 Figure 95: Europe Clinical Biomarkers Market, $Million, 2021-2032 Figure 96: Europe: Market Dynamics Figure 97: Europe Clinical Biomarkers Market (by Country), $Million, 2021-2032 Figure 98: Germany Clinical Biomarkers Market, $Million, 2021-2032 Figure 99: Share of Cancer Cases in Germany, 2020 Figure 100: France Clinical Biomarkers Market, $Million, 2021-2032 Figure 101: U.K. Clinical Biomarkers Market, $Million, 2021-2032 Figure 102: Italy Clinical Biomarkers Market, $Million, 2021-2032 Figure 103: Spain Clinical Biomarkers Market, $Million, 2021-2032 Figure 104: Rest-of-Europe Clinical Biomarkers Market, $Million, 2021-2032 Figure 105: Asia-Pacific Clinical Biomarkers Market, $Million, 2021-2032 Figure 106: Asia-Pacific Clinical Biomarkers Market (by Country), $Million, 2021-2032 Figure 107: Asia-Pacific: Market Dynamics Figure 108: China Clinical Biomarkers Market, $Million, 2021-2032 Figure 109: India Clinical Biomarkers Market, $Million, 2021-2032 Figure 110: Japan Clinical Biomarkers Market, $Million, 2021-2032 Figure 111: South Korea Clinical Biomarkers Market, $Million, 2021-2032 Figure 112: Australia Clinical Biomarkers Market, $Million, 2021-2032 Figure 113: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Million, 2021-2032 Figure 114: Latin America Clinical Biomarkers Market, $Million, 2021-2032 Figure 115: Latin America: Market Dynamics Figure 116: Latin America Clinical Biomarkers Market (by Country), $Million, 2021-2032 Figure 117: Brazil Clinical Biomarkers Market, $Million, 2021-2032 Figure 118: Mexico Clinical Biomarkers Market, $Million, 2021-2032 Figure 119: Rest-of-Latin America Clinical Biomarkers Market, $Million, 2021-2032 Figure 120: Rest-of-the-World) Clinical Biomarkers Market, $Million, 2021-2032 Figure 121: Total Number of Companies Profiled Figure 122: Abbott.: Product Portfolio Figure 123: Abbott.: Overall Financials, $Million, 2019-2021 Figure 124: Abbott.: Revenue (by Segment), $Million, 2019-2021 Figure 125: Abbott.: Revenue (by Region), $Million, 2019-2021 Figure 126: Abbott.: R&D Expenditure, $Million, 2019-2021 Figure 127: Agilent Technologies, Inc.: Product Portfolio Figure 128: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021 Figure 129: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 130: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 131: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 132: Bio-Rad Laboratories, Inc.: Product Portfolio Figure 133: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021 Figure 134: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 135: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 136: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 137: Illumina, Inc.: Product Portfolio Figure 138: Illumina, Inc.: Overall Financials, $Million, 2019-2021 Figure 139: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 140: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 141: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 142: PerkinElmer Inc.: Product Portfolio Figure 143: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021 Figure 144: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 145: PerkinElmer Inc.: Revenue (by Region), $Million, 2019-2021 Figure 146: PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021 Figure 147: QIAGEN N.V.: Product Portfolio Figure 148: QIAGEN N.V.: Overall Financials, $Million, 2019-2021 Figure 149: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021 Figure 150: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021 Figure 151: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021 Figure 152: Thermo Fisher Scientific Inc.: Product Portfolio Figure 153: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021 Figure 154: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 155: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021 Figure 156: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021 Figure 157: NeoGenomics Laboratories: Service Portfolio Figure 158: NeoGenomics Laboratories: Overall Financials, $Million 2019-2021 Figure 159: NeoGenomics Laboratories: Revenue (by Segment), 2019-2021 Figure 160: NeoGenomics Laboratories: R&D Expenditure, 2019-2021 Figure 161: Charles River Laboratories: Service Portfolio Figure 162: Charles River Laboratories: Overall Financials, $Million, 2019-2021 Figure 163: Charles River Laboratories: Revenue (by Segment), $Million, 2019-2021 Figure 164: Charles River Laboratories.: Revenue (by Region), $Million, 2019-2021 Figure 165: F. Hoffmann-La Roche Ltd: Product Portfolio Figure 166: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021 Figure 167: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021 Figure 168: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021 Figure 169: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021 Figure 170: Quest Diagnostics Incorporated, Inc.: Service Portfolio Figure 171: Quest Diagnostics Incorporated: Overall Financials, $Million, 2019-2021 Figure 172: Quest Diagnostics Incorporated.: Revenue (by Segment), $Million, 2019-2021 Figure 173: Enzo Biochem Inc.: Product Portfolio Figure 174: Enzo Biochem Inc.: Overall Financials, $Million, 2019-2021 Figure 175: Enzo Biochem Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 176: Enzo Biochem Inc.: Revenue (by Region), $Million, 2019-2021 Figure 177: Enzo Biochem Inc.: R&D Expenditure, 2019-2021 Figure 178: ALCEN.: Service Portfolio Figure 179: Myriad Genetics, Inc.: Service Portfolio Figure 180: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021 Figure 181: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 182: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 183: CENTOGENE N.V.: Service Portfolio Figure 184: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021 Figure 185: CENTOGENE N.V.: Revenue (by Segment), $Million, 2019-2021 Figure 186: CENTOGENE N.V.: Revenue (by Region), $Million, 2019-2021 Figure 187: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021 Figure 188: bioMérieux S.A.: Product Portfolio Figure 189: bioMérieux S.A.: Overall Financials, $Million, 2019-2021 Figure 190: bioMérieux S.A.: Revenue (by Segment), $Million, 2019-2021 Figure 191: bioMérieux S.A.: Revenue (by Region), $Million, 2019-2021 Figure 192: Arsenal Capital Partners: Services Portfolio Figure 193: Novogene Co., Ltd.: Service Portfolio Figure 194: Q2 Solutions: Service Portfolio Figure 195: Caris Life Sciences: Service Portfolio Figure 196: Broad Institute: Service Portfolio Figure 197: Personalis Inc.: Service Portfolio Figure 198: Personalis Inc.: Overall Financials, $Million, 2019-2021 Figure 199: Personalis Inc.: R&D Expenditure, $Million, 2019-2021 Figure 200: Azenta Life Sciences: Service Portfolio Figure 201: Discovery Life Sciences: Service Portfolio Figure 202: BGI: Service Portfolio Figure 203: Eurofins Scientific: Service Portfolio Figure 204: Eurofins Scientific: Overall Financials, $Million, 2019-2021 Figure 205: Eurofins Scientific: Revenue (by Region), $Million, 2019-2021 Figure 206: Becton, Dickinson and Company: Product Portfolio Figure 207: Becton, Dickinson and Company: Overall Financials, $Million, 2019-2021 Figure 208: Becton, Dickinson and Company: Revenue (by Region), $Million, 2019-2021 Figure 209: Becton, Dickinson and Company: R&D Expenditure, $Million, 2019-2021 List of Tables Table 1: COVID-19 Impact on Global Clinical Biomarkers Market Table 2: Key Player Initiatives Table 3: Pricing List of Product/Service Table 4: List of Product/Service and its Technology Table 5: Global Clinical Biomarkers Market: Key Players Patent Portfolio Table 6: Example of Efficacy Biomarker Table 7: Examples of Diagnostic Biomarker Table 8: Examples of Prognostic Biomarker Table 9: Examples of Safety Biomarker Table 10: Example of Clinical Biomarker Service Table 11: Next-Generation Sequencing-Based Clinical Biomarker Products Table 12: Polymerase Chain Reaction-Based Clinical Biomarker Products Table 13: Immunohistochemistry (IHC)-Based Clinical Biomarker Products Table 14: ELISA-Based Clinical Biomarker Products Table 15: Companies Offering Other Technologies-Based Products Table 16: Example of Cancer Biomarker Table 17: Example of  Cardiac Biomarker Table 18: Example of  Neurological Biomarker Table 19: Examples of Infectious Disease Biomarker Table 20: Estimated Cancer Deaths in California, 2022

Company Mentioned

Abbott. Agilent Technologies, Inc. Bio-Rad Laboratories, Inc. Illumina, Inc. PerkinElmer Inc. QIAGEN N.V. Thermo Fisher Scientific Inc. NeoGenomics Laboratories Charles River Laboratories F. Hoffmann-La Roche Ltd Quest Diagnostics Incorporated Enzo Biochem Inc. ALCEN Myriad Genetics, Inc. CENTOGENE N.V. bioMérieux S.A. Arsenal Capital Partners Novogene Co., Ltd. Q2 Solutions Caris Life Sciences Broad Institute Personalis Inc. Azenta Life Sciences Discovery Life Sciences(DLS) BGI Eurofins Scientific Becton, Dickinson and Company

Reviews

There are no reviews yet.

Be the first to review “Clinical Biomarkers – A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, Application, End User, and Region – Analysis and Forecast, 2022-2032”